Neurizon Therapeutics Limited (NUZ.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.086 (-2.27%) as of
Key statistics
- Market cap
- 68.08M
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0530 – 0.1300
- Beta
- 1.20
- Revenue (TTM)
- 17.59M
- Profit margin
- -60.98%
- Analyst target
- A$0.485
- Volume
- 436.06k
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.